Showing results (241-250 of 289) with videos related to
Sort By:
Pageof 29
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 20, 2017
Association of Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk of primary open angle glaucomaJose Navarro-Partida, Abril Bernardette Martinez-Rizo, Pedro Ramirez-Barrera, et al.The New England Journal of Medicine|September 16, 2024
Preoperative Chemoradiotherapy for Resectable Gastric CancerTrevor Leong, B Mark Smithers, Michael Michael, et al.The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.Journal of Diabetes Research|July 20, 2026
Expression Signatures of Vascular Complication-Associated Proteins in Type 2 Diabetes: A Multiomics Analysis From the FIELD StudyHabib Francis, Andrzej S Januszewski, Abubakar S Mangani, et al.Clinical Colorectal Cancer|November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyJeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.International Journal of Radiation Oncology, Biology, Physics|April 3, 2020
Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK TrialPaul Keall, Doan Trang Nguyen, Ricky O'Brien, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.Pageof 29